Top Story

First-line afatinib extended OS in exon 19 deletion-positive lung adenocarcinoma

January 30, 2015

Patients with lung adenocarcinoma who harbored exon 19 deletion EGFR mutations experienced significantly longer OS when treated with first-line afatinib instead of chemotherapy, according to analyses of results from two phase 3 trials.

However, researchers did not observe the survival benefit among patients with other types of EGFR mutations.

In the Journals

Additional CT scans increased risk for second primary malignancy in patients with non-Hodgkin's lymphoma

January 30, 2015
Patients with non-Hodgkin’s lymphoma who underwent more frequent surveillance CT scans demonstrated an increased risk for a secondary primary malignancy, according…
In the JournalsPerspective

GTX effective neoadjuvant treatment in locally advanced pancreatic cancer

January 29, 2015
Patients with locally advanced, unresectable pancreatic adenocarcinoma experienced favorable survival when they received neoadjuvant gemcitabine, docetaxel and…
FDA News

Tarextumab granted orphan drug designation for pancreatic, small cell lung cancers

January 29, 2015
The FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small cell lung cancer, the drug’s manufacturer announced…
In the Journals

Teledermoscopy accepted by patients, effective in monitoring atypical nevi

January 29, 2015
Patients were receptive to the use of teledermoscopy, which was effective for short-term monitoring of clinically atypical nevi, according to recently published study…
More News Headlines »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan
morganatic-roan